Halozyme Therapeutics, Inc, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc, entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC. These three agreements are expected to cover the commercial production of recombinant human hyaluronidase (rHuPH20) to be used in the manufacture of both current products as well as certain partnered product candidates such as subcutaneous Herceptin and Gammagard with rHuPH20. Subcutaneous Herceptin and Gammagard with rHuPH20 are both currently in phase-3 clinical trials.
"We are pleased to strengthen our already robust supply chain for rHuPH20 by securing these commercial supply agreements to support existing products as well as exciting partnered product candidates such as subcutaneous Herceptin and Gammagard with rHuPH20," stated Jonathan E Lim, Halozyme's president and CEO.
Specific financial terms of these commercial supply agreements have not been disclosed.
Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets.